Scarica l'app Stockscreener
12.91
4.72%
-0.64
Dopo l'orario di chiusura:
12.91
Precedente Chiudi:
$13.55
Aprire:
$13.58
Volume 24 ore:
955.84K
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.13B
Reddito:
-
Utile/perdita netta:
$-185.15M
Rapporto P/E:
-6.3744
EPS:
-2.0253
Flusso di cassa netto:
$-148.72M
1 W Prestazione:
-7.52%
1M Prestazione:
-15.57%
6M Prestazione:
-54.09%
1 anno Prestazione:
+150.68%
Intervallo 1D:
$12.87
$14.01
Intervallo di 1 settimana:
$12.87
$14.29
Portata 52W:
$3.89
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Nome
Olema Pharmaceuticals Inc
Settore
Industria
Telefono
(415) 651-3316
Indirizzo
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
12.91 | 1.18B | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
437.22 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.74 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
820.63 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.00 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-19 | Ripresa | Jefferies | Buy |
| 2026-02-11 | Iniziato | Stifel | Buy |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-12 | Reiterato | Citigroup | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2024-01-30 | Iniziato | Citigroup | Buy |
| 2023-07-21 | Iniziato | Oppenheimer | Outperform |
| 2023-05-05 | Iniziato | CapitalOne | Overweight |
| 2023-02-22 | Iniziato | Credit Suisse | Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Iniziato | H.C. Wainwright | Neutral |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2020-12-14 | Iniziato | Canaccord Genuity | Buy |
| 2020-12-14 | Iniziato | Cowen | Outperform |
| 2020-12-14 | Iniziato | JP Morgan | Overweight |
| 2020-12-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Olema Pharmaceuticals Inc Borsa (OLMA) Ultime notizie
Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy - Moomoo
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Tr - GuruFocus
Olema Oncology inks clinical trial collaboration with Bayer - The Pharma Letter
Olema Oncology and Bayer Partner on Clinical Trial to Evaluate OP-3136 and NUBEQA® in Metastatic Castration-Resistant Prostate Cancer 1 - Minichart
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Trial - GuruFocus
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer - The Manila Times
Olema oncology announces clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with Nubeqa® (darolutamide) in metastatic castration-resistant prostate cancer - marketscreener.com
Olema Oncology (NASDAQ: OLMA) inks Bayer trial deal for OP-3136 combo - Stock Titan
New prostate cancer trial pairs Olema drug with Bayer’s NUBEQA - Stock Titan
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap - Yahoo Finance
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Olema Oncology sees early hope as cancer drug shows tumor shrinkage in phase 1 study - MSN
Olema Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:OLMA - Benzinga
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study - Yahoo Finance
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Olema Oncology Reports Promising Phase 1 Results for OP-3136 KAT6 Inhibitor in Advanced Solid Tumors at 2026 ASCO Meeting 12 - Minichart
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - Sahm
Olema reports phase 1 data for cancer drug OP-3136 By Investing.com - Investing.com South Africa
Olema reports phase 1 data for cancer drug OP-3136 - Investing.com UK
Olema Pharmaceuticals Reports Promising Initial Data for OP-3136 in Phase 1 Study Evaluating KAT6 Inhibitor for Advanced Solid Tumors - Quiver Quantitative
Olema Oncology (NASDAQ: OLMA) shares early OP-3136 Phase 1 cancer data - Stock Titan
Early cancer trial sees tumor shrinkage in 13 of 19 on Olema drug - Stock Titan
Olema Pharmaceuticals (OLMA) Valuation After Encouraging New OP-3136 Phase 1 Data - Sahm
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Quiver Quantitative
Breast cancer-focused Olema plans 3 investor talks across May and June - Stock Titan
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $52 - Moomoo
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Olema Pharmaceuticals (OLMA) Deepens Trial Spend With Ample Cash Buffer Is Its Risk-Reward Now Clearer? - Sahm
Olema Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Bain Capital (OLMA) discloses 8.2% position including pre-funded warrant - Stock Titan
Janus Henderson (NASDAQ: OLMA) discloses 7.11M shares, 8.2% stake - Stock Titan
Olema: The Market Overreacted To Roche's SERD Failure - Seeking Alpha
Legal operations leadership role opens as Olema Pharmaceuticals launches search for senior manager - Traders Union
Olema Oncology (OLMA) Gains Attention with Upcoming Clinical Res - GuruFocus
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $23 to $48 - Moomoo
Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
OLMA Maintained by Guggenheim -- Price Target Lowered to $35.00 - GuruFocus
OpenAI pushed this startup out of San Francisco, but it found a brand-new space elsewhere - The Business Journals
Guggenheim cuts Olema Pharmaceuticals stock price target on trial timing By Investing.com - Investing.com Canada
TradingKey - TradingKey
Olema Pharmaceuticals Q1 Net Loss Widens - Moomoo
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Olema Oncology (OLMA) Focuses on Advancing Breast Cancer Treatme - GuruFocus
How to Value Olema Pharmaceuticals (OLMA) After Q1 2026 Earnings - GuruFocus
Olema Oncology Announces Q1 2026 Financial Results and Upcoming Phase 3 Breast Cancer Trial Data - Minichart
Olema Pharmaceuticals Inc Azioni (OLMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):